Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its target price raised by stock analysts at B. Riley from $32.00 to $46.00 in a research note issued to investors on Monday, BenzingaRatingsTable reports. The firm presently has a “buy” rating on the biotechnology company’s stock. B. Riley’s target price would suggest a potential upside of 36.42% from the company’s previous close.

A number of other equities research analysts have also recently commented on the company. TheStreet raised Arrowhead Pharmaceuticals from a “d” rating to a “c+” rating in a report on Thursday, May 30th. ValuEngine cut Arrowhead Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, August 1st. Cantor Fitzgerald cut Arrowhead Pharmaceuticals from an “overweight” rating to a “neutral” rating and set a $24.00 price target on the stock. in a report on Thursday, June 27th. BidaskClub raised Arrowhead Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, July 19th. Finally, Piper Jaffray Companies raised their price target on Arrowhead Pharmaceuticals from $33.00 to $50.00 and gave the company an “overweight” rating in a report on Tuesday, August 6th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $33.70.

Shares of Arrowhead Pharmaceuticals stock opened at $33.72 on Monday. The stock’s fifty day moving average is $28.82 and its 200 day moving average is $22.49. The stock has a market cap of $3.16 billion, a P/E ratio of -51.88 and a beta of 1.59. Arrowhead Pharmaceuticals has a one year low of $10.41 and a one year high of $34.02.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its quarterly earnings results on Monday, August 5th. The biotechnology company reported $0.21 EPS for the quarter, missing the Zacks’ consensus estimate of $0.34 by ($0.13). The business had revenue of $42.70 million for the quarter, compared to the consensus estimate of $59.05 million. Arrowhead Pharmaceuticals had a net margin of 33.28% and a return on equity of 26.27%. As a group, equities research analysts anticipate that Arrowhead Pharmaceuticals will post 0.73 EPS for the current fiscal year.

In other news, Director Mauro Ferrari sold 17,756 shares of Arrowhead Pharmaceuticals stock in a transaction dated Wednesday, June 26th. The stock was sold at an average price of $27.61, for a total value of $490,243.16. Following the sale, the director now directly owns 1,900 shares of the company’s stock, valued at $52,459. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, General Counsel Patrick O’brien sold 30,000 shares of Arrowhead Pharmaceuticals stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $24.88, for a total value of $746,400.00. Following the completion of the sale, the general counsel now directly owns 203,000 shares in the company, valued at $5,050,640. The disclosure for this sale can be found here. Insiders own 4.80% of the company’s stock.

Hedge funds have recently modified their holdings of the company. Rhumbline Advisers increased its holdings in shares of Arrowhead Pharmaceuticals by 7.2% in the first quarter. Rhumbline Advisers now owns 124,276 shares of the biotechnology company’s stock worth $2,280,000 after purchasing an additional 8,313 shares during the last quarter. Bank of America Corp DE increased its holdings in shares of Arrowhead Pharmaceuticals by 812.8% in the fourth quarter. Bank of America Corp DE now owns 333,938 shares of the biotechnology company’s stock worth $4,148,000 after purchasing an additional 380,784 shares during the last quarter. Virginia Retirement Systems ET AL bought a new stake in shares of Arrowhead Pharmaceuticals in the first quarter worth about $391,000. Bailard Inc. increased its holdings in shares of Arrowhead Pharmaceuticals by 50.5% in the first quarter. Bailard Inc. now owns 165,600 shares of the biotechnology company’s stock worth $3,039,000 after purchasing an additional 55,600 shares during the last quarter. Finally, Strs Ohio increased its holdings in shares of Arrowhead Pharmaceuticals by 109.5% in the second quarter. Strs Ohio now owns 26,400 shares of the biotechnology company’s stock worth $699,000 after purchasing an additional 13,800 shares during the last quarter. 73.52% of the stock is currently owned by hedge funds and other institutional investors.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's pipeline include ARO-AAT, a RNA interference (RNAi) therapeutic candidate for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3 to treat hypertriglyceridemia; ARO-ANG3 to reduce production of angiopoietin-like protein 3; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma.

Further Reading: What Factors Can Affect Return on Equity?

Analyst Recommendations for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.